Table 3.
Time to absolute neutrophil count and platelet count recovery by antifungal
| Concomitant azole | Antifungal agent | CYP3A4 inhibitor | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Yes (N=47) | No (N=17) | PCZ (N=17) | VCZ (N=9) | ISA (N=20) | ECHINO (N=17) | None (N=17) | Moderate (N=21) | Strong (N=26) | |
| ANC>500—n(%) | 45 (96%) | 14 (82%) | 17 (100%) | 9 (100%) | 18 (90%) | 14 (82%) | 14 (82%) | 19 (90%) | 26 (100%) |
| Median days to ANC>500 (95% CI) | 34 (33, 37) | 34 (28, NA) | 35 (33, 39) | 35 (26, NA) | 34 (32, 47) | 34 (28, NA) | 34 (28, NA) | 34 (31, 45) | 34 (33, 38) |
| ANC>1000—n(%) | 41 (87%) | 10 (59%) | 17 (100%) | 7 (78%) | 16 (80%) | 10 (59%) | 10 (59%) | 17 (81%) | 24 (92%) |
| Median days to ANC>1000 (95% CI) | 37 (34, 38) | 39 (30, NA) | 35 (33, 40) | 38 (30, NA) | 37 (33, NA) | 39 (30, NA) | 39 (30, NA) | 34 (32, NA) | 37 (34, 40) |
| PLT>50—n(%) | 42 (89%) | 17 (100%) | 15 (88%) | 8 (89%) | 18 (90%) | 17 (100%) | 17 (100%) | 19 (91%) | 23 (89%) |
| Median days to PLT>50 (95% CI) | 26 (23, 29)α | 19 (16, 23)α | 25 (21, 50)α | 28 (25, NA)α | 25 (19, 29)α | 19 (16, 23)α | 19 (16, 23)α | 25 (19, 29)α | 27 (22, 37)α |
| PLT>100—n(%) | 39 (83%) | 17 (100%) | 14 (82%) | 8 (89%) | 16 (80%) | 17 (100%) | 17 (100%) | 17 (81%) | 22 (85%) |
| Median days to PLT>100 (95% CI) | 28 (23, 34)β | 22 (20, 25)β | 26 (23, NA) | 32 (30, NA) | 27 (21, 35) | 22 (20, 25) | 22 (20, 25)β | 27 (21, 35)β | 31 (23, 41)β |
ANC: absolute neutrophil count (cells/mm3); PLT: platelet count (cells/mm3); PCZ: posaconazole; VCZ: voriconazole; ISA: isavuconazole; ECHINO: echinocandin
α
p<0.05 for difference in median days to PLT50 within group
β
p<0.05 for difference in median days to PLT100 within group; shaded cells represent p<0.05 for within group comparisons